Search
Doripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnDoripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. … Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections.
Piperazine
go.drugbank.com/drugs/DB00592ApprovedVet approvedWithdrawnOutside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. … Piperazine compounds mediate their anthelmintic action by generally paralyzing parasites, allowing the host body to easily remove or expel the invading organism.
Amobarbital
go.drugbank.com/drugs/DB01351ApprovedIllicitA barbiturate with hypnotic and sedative properties (but not antianxiety). … Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)
Third-degree atrioventricular block
go.drugbank.com/conditions/DBCOND0108204Drugs: EpinephrineSynonyms: High grade atrioventricular blockQuinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnQuinagolide is currently available in several countries including Canada, but not approved for treatment in the United States. … Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the (-) enantiomer.
Indacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIndacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. … It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler.
Chloramphenicol
go.drugbank.com/drugs/DB00446ApprovedInvestigationalVet approvedWithdrawnAn antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. … (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this
Recombinant stabilized RSV B prefusion F antigen
go.drugbank.com/drugs/DB18714ApprovedInvestigational[L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of
Treprostinil
go.drugbank.com/drugs/DB00374ApprovedInvestigationalTreprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. … [L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life.
Diroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigationalMultiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. … This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure.